|View printer-friendly version|
|Array BioPharma Files Registration Statement For Public Offering of Common Stock|
|BOULDER, Jan. 16 /PRNewswire-FirstCall/ -- Array BioPharma Inc. (Nasdaq: ARRY)
today announced that it has filed a registration statement with the Securities
and Exchange Commission relating to a potential public offering by Array of
4,200,000 shares of its common stock. All shares will be offered by the company.
In addition, the underwriters will have an option to purchase up to an
additional 630,000 shares of common stock from Array and selling stockholders
solely to cover over-allotments, if any.
The transaction will be lead managed by Lehman Brothers Inc. and co-managed by UBS Warburg, Legg Mason Wood Walker, Incorporated and Thomas Weisel Partners LLC.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell nor the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.
When available, a preliminary prospectus relating to these securities may be obtained from ADP Prospectus Department in care of Lehman Brothers Inc. at 55 Mercedes Way, Edgewood, NY 11717. Requests for a preliminary prospectus may be made by Fax: (631) 254-7268, and questions may be directed to (631) 254-7106.
Array BioPharma is a drug discovery company inventing new small molecule drugs through the integration of chemistry, biology and informatics. The company collaborates with leading pharmaceutical and biotechnology companies to identify novel small molecule drugs using the Array Discovery Platform. The company leverages this integrated approach to small molecule drug discovery to develop its own pipeline of proprietary drug candidates. For more information on Array BioPharma, please visit the company's web site at www.arraybiopharma.com .
SOURCE Array BioPharma Inc.
CONTACT: Tricia Haugeto of Array BioPharma Inc., +1-303-386-1193, email@example.com